Literature DB >> 16966559

Characteristics and antecedents of progressive multifocal leukoencephalopathy in an insured population.

P M Eng1, B R Turnbull, S F Cook, J E Davidson, T Kurth, J D Seeger.   

Abstract

Based on health insurance claims from a large U.S. health insurer, the authors identified 44 progressive multifocal leukoencephalopathy (PML) cases from 2002 through 2004 and described their characteristics, including antecedent diagnoses and treatments as well as survival. Immunosuppressive conditions such as HIV/AIDS, rather than potentially immunosuppressive treatments, were the main antecedents of PML. A lower mortality was observed among PML patients whose antecedent diagnosis was HIV/AIDS, the majority of whom received highly active antiretroviral therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16966559     DOI: 10.1212/01.wnl.0000233918.21986.9c

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  12 in total

Review 1.  Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis.

Authors:  Chen S Tan; Igor J Koralnik
Journal:  Lancet Neurol       Date:  2010-04       Impact factor: 44.182

Review 2.  [Demyelinating disorders].

Authors:  T Weber; W Köhler
Journal:  Nervenarzt       Date:  2010-04       Impact factor: 1.214

3.  Immune suppression of JC virus gene expression is mediated by SRSF1.

Authors:  Rahsan Sariyer; Francesca Isabella De-Simone; Jennifer Gordon; Ilker Kudret Sariyer
Journal:  J Neurovirol       Date:  2016-03-07       Impact factor: 2.643

4.  Progressive necrotic encephalopathy following tacrolimus therapy for liver transplantation.

Authors:  Paolo Aridon; Paolo Ragonese; Norma Di Benedetto; Giovanni Grasso; Pier Giulio Conaldi; Marco D'Amelio; Giovanni Savettieri
Journal:  Neurol Sci       Date:  2009-09-25       Impact factor: 3.307

5.  Inflammatory infratentorial progressive multifocal leukoencephalopathy in a patient with rheumatoid arthritis.

Authors:  Boleslaw Lach; Barbara Connolly; Christian Wüthrich; Igor J Koralnik
Journal:  Neuropathology       Date:  2013-05-20       Impact factor: 1.906

Review 6.  [Progressive multifocal leukoencephalopathy and rheumatic disease].

Authors:  C Kneitz; H Wiendl
Journal:  Z Rheumatol       Date:  2008-07       Impact factor: 1.372

7.  SF2/ASF binding region within JC virus NCCR limits early gene transcription in glial cells.

Authors:  Elena Uleri; Patrick Regan; Antonina Dolei; Ilker Kudret Sariyer
Journal:  Virol J       Date:  2013-05-14       Impact factor: 4.099

8.  Regulation of human neurotropic JC virus replication by alternative splicing factor SF2/ASF in glial cells.

Authors:  Ilker Kudret Sariyer; Kamel Khalili
Journal:  PLoS One       Date:  2011-01-31       Impact factor: 3.240

9.  The national incidence of PML in Sweden, 1988-2013.

Authors:  Ellen Iacobaeus; Sarah Burkill; Shahram Bahmanyar; Ramil Hakim; Camilla Byström; Michael Fored; Tomas Olsson; Lou Brundin; Scott Montgomery
Journal:  Neurology       Date:  2018-01-10       Impact factor: 9.910

10.  Natalizumab in the treatment of multiple sclerosis.

Authors:  Brandon A Brown
Journal:  Ther Clin Risk Manag       Date:  2009-08-03       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.